|
1
|
Brook RD, Franklin B, Cascio W, Hong Y,
Howard G, Lipsett M, Luepker R, Mittleman M, Samet J, Smith SC Jr,
et al: Air pollution and cardiovascular disease: A statement for
healthcare professionals from the expert panel on population and
prevention science of the American heart association. Circulation.
109:2655–2671. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nel AE, Mädler L, Velegol D, Xia T, Hoek
EM, Somasundaran P, Klaessig F, Castranova V and Thompson M:
Understanding biophysicochemical interactions at the nano-bio
interface. Nat Mater. 8:543–557. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morimoto Y and Tanaka I: Effects of
nanoparticles on humans. Sangyo Eiseigaku Zasshi. 50:37–48.
2008.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adachi T, Takahara K, Taneo J, Uchiyama Y
and Inaba K: Particle size of latex beads dictates IL-1β production
mechanism. PLoS One. 8:e684992013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tada-Oikawa S, Ichihara G, Fukatsu H,
Shimanuki Y, Tanaka N, Watanabe E, Suzuki Y, Murakami M, Izuoka K,
Chang J, et al: Titanium dioxide particle type and concentration
influence the inflammatory response in Caco-2 cells. Int J Mol Sci.
17:5762016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsumoto N, Ariga A, To-e S, Nakamura H,
Agata N, Hirano S, Inoue J and Umezawa K: Synthesis of NF-kappaB
activation inhibitors derived from epoxyquinomicin C. Bioorg Med
Chem Lett. 10:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ariga A, Namekawa J, Matsumoto N, Inoue J
and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced
nuclear translocation and activation of NF-kappaB by
dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto M, Horie R, Takeiri M, Kozawa I
and Umezawa K: Inactivation of NF-kappaB components by covalent
binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine
residues. J Med Chem. 51:5780–5788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeiri M, Horie K, Takahashi D, Watanabe
M, Horie R, Simizu S and Umezawa K: Involvement of DNA binding
domain in the cellular stability and importin affinity of NF-κB
component RelB. Org Biomol Chem. 10:3053–3059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimada C, Ninomiya Y, Suzuki E and
Umezawa K: Efficient cellular uptake of the novel NF-kappaB
inhibitor (−)-DHMEQ and irreversible inhibition of NF-kappaB in
neoplastic cells. Oncol Res. 18:529–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kozawa I, Kato K, Teruya T, Suenaga K and
Umezawa K: Unusual intramolecular N->O acyl group migration
occurring during conjugation of (−)-DHMEQ with cysteine. Bioorg Med
Chem Lett. 19:5380–5382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Umezawa K: Peritoneal NF-κB as a possible
molecular target for suppression of various cancers and
inflammation. ForumImmun Dis Ther. 4:63–77. 2013. View Article : Google Scholar
|
|
13
|
Lin Y, Ukaji T, Koide N and Umezawa K:
Inhibition of late and early phases of cancer metastasis by NF-κB
inhibitor DHMEQ derived from microbial bioactive metabolite
epoxyquinomicin: A review. Int J Mol Sci. 19:7292018. View Article : Google Scholar :
|
|
14
|
Suzuki E and Umezawa K: Inhibition of
macrophage activation and phagocytosis by a novel NF-kappaB
inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother.
60:578–586. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki E, Sugiyama C and Umezawa K:
Inhibition of inflammatory mediator secretion by (−)-DHMEQ in mouse
bone marrow-derived macrophages. Biomed Pharmacother. 63:351–358.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sosińska P, Baum E, Maćkowiak B,
Staniszewski R, Jasinski T, Umezawa K and Bręborowicz A: Inhibition
of NF-kappaB with dehydroxyepoxiquinomicin modifies function of
human peritoneal mesothelial cells. Am J Transl Res. 8:5756–5765.
2016.PubMed/NCBI
|
|
17
|
Suzuki Y, Sugiyama C, Ohno O and Umezawa
K: Preparation and biological activities of optically active
dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor.
Tetrahedron. 60:7061–7066. 2004. View Article : Google Scholar
|
|
18
|
Andrews NC and Faller DV: A rapid
micropreparation technique for extraction of DNA-binding proteins
from limiting numbers of mammalian cells. Nucleic Acids Res.
19:24991991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pétrilli V, Papin S, Dostert C, Mayor A,
Martinon F and Tschopp J: Activation of the NALP3 inflammasome is
triggered by low intracellular potassium concentration. Cell Death
Differ. 14:1583–1589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hussain S, Vanoirbeek JA, Luyts K, De
Vooght V, Verbeken E, Thomassen LC, Martens JA, Dinsdale D, Boland
S, Marano F, et al: Lung exposure to nanoparticles modulates an
asthmatic response in a mouse model. Eur Respir J. 37:299–309.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bomsztyk K, Rooney WJ, Iwasaki T, Rachie
AN, Dower KS and Sibley HC: Evidence that interleukin-1 and phorbol
esters activate NF-kappaB by different pathways: Role of protein
kinase C. Cell Regul. 2:329–335. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Watanabe M, Ohsugi T, Shoda M, Ishida T,
Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y,
Kamihira S, et al: Dual targeting of transformed and untransformed
HTLV-1-infected T-cells by DHMEQ, a potent and selective inhibitor
of NF-kappaB, as a strategy for chemoprevention and therapy of
adult T cell leukemia. Blood. 106:2462–2471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Horie R, Watanabe M, Okamura T, Taira M,
Shoda M, Motoji T, Utsunomiya A, Watanabe T, Higashihara M and
Umezawa K: DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and
enhances fludarabine effects on chronic lymphocytic leukemia cells.
Leukemia. 20:800–806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morishige T, Yoshioka Y, Tanabe A, Yao X,
Tsunoda S, Tsutsumi Y, Mukai Y, Okada N and Nakagawa S: Titanium
dioxide induces different levels of IL-1beta production dependent
on its particle characteristics through caspase-1 activation
mediated by reactive oxygen species and cathepsin B. Biochem
Biophys Res Commun. 392:160–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Youm YH, Nguyen KY, Grant RW, Goldberg EL,
Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti
TD, et al: The ketone metabolite β-hydroxybutyrate blocks NLRP3
inflammasome-mediated inflammatory disease. Nat Med. 21:263–269.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fink SL and Cookson BT: Apoptosis,
pyroptosis, and necrosis: Mechanistic description of dead and dying
eukaryotic cells. Infect Immun. 73:1907–1916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yazdi AS, Guarda G, Riteau N, Drexler SK,
Tardivel A, Couillin I and Tschopp J: Nanoparticles activate the
NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause
pulmonary inflammation through release of IL-1α and IL-1β. Proc
Natl Acad Sci USA. 107:19449–19454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van de Veerdonk LF, Smeekens PS, Joosten
BAL, Kullberg JB, Dinarello AC, van der Meer MWJ and Netea GM:
Reactive oxygen species-independent activation of the IL-1β
inflammasome in cells from patients with chronic granulomatous
disease. Proc Natl Acad Sci USA. 107:3030–3033. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iyer SS, He Q, Janczy JR, Elliott EI,
Zhong Z, Olivier AK, Sadler JJ, Knepper-Adrian V, Han R, Qiao L, et
al: Mitochondrial cardiolipin is required for Nlrp3 inflammasome
activation. Immunity. 39:311–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hamasaka A, Yoshioka N, Abe R, Kishino S,
Umezawa K, Ozaki M, Todo S and Shimizu H: Topical application of
dehydroxymethylepoxyquinomicinimproves allergic inflammation via
NF-kappaB inhibition. J Allergy Clin Immunol. 126:400–403. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang X, Lan Y, Wei B, Dai C, Gu Y, Ma J,
Liu X, Umezawa K and Zhang Y: External application of NF-κB
inhibitor DHMEQ suppresses development of atopic dermatitis-like
lesions induced with DNCB/OX in BALB/c mice. Immunopharmacol
Immunotoxicol. 39:157–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shimo T, Adachi Y, Umezawa K, Okigaki M,
Takaya J, Taniuchi S, Ikehara S and Kaneko K:
Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis
factor-α production in lipopolysaccharide-injected mice, resulting
in rescuing mice from death in vivo. Clin Exp Immunol. 166:299–306.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shimizu K, Konno S, Ozaki M, Umezawa K,
Yamashita K, Todo S and Nishimura M: Dehydroxymethylepoxyquinomicin
(DHMEQ), a novel NF-kappa B inhibitor, inhibits allergic
inflammation and airway remodelling in murine models of asthma.
Clin Exp Allergy. 42:1273–1281. 2012. View Article : Google Scholar : PubMed/NCBI
|
